WeVote
Log In

Bill

Bill

HD 340

An Act ensuring access to specialty medications

194th Legislature (2025-2026) Introduced by Dan Sena

Massachusetts bill requiring insurers to expedite specialty medication approvals and limit patient cost-sharing for high-cost drugs to improve treatment access.

0
WeVote Research Nonpartisan
Bill Summary · HD 340

Legislative bill overview

HD 340 requires health insurance plans in Massachusetts to ensure timely access to specialty medications, including provisions for expedited prior authorization reviews and limitations on cost-sharing for these high-cost drugs. The bill aims to reduce barriers patients face when obtaining specialized treatments for conditions like cancer, autoimmune diseases, and rare disorders.

Why is this important

Specialty medications often cost thousands of dollars monthly and are frequently subject to restrictive insurance approval processes that can delay critical treatment. Patients with serious illnesses may experience disease progression or worsening outcomes during authorization delays, making access speed a direct health equity issue alongside affordability concerns.

Potential points of contention

  • Insurance industry costs: Carriers argue expanded specialty drug access without comparable cost controls will increase premiums for all members, potentially pricing out younger/healthier enrollees
  • Prior authorization scope: Defining which medications qualify and what "timely" review means (24-48 hours?) creates implementation disputes between insurers and providers
  • Cost-sharing caps: Whether limits on copays/coinsurance (often 20-50% of specialty drug costs) unfairly shift costs to non-specialty drug users through higher overall premiums

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.